Lenalidomide Capsule
Product Images NDC 63304-044

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 63304-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 02)

FDA Label Image

Image 2 (Image 03)

FDA Label Image

Label 1 (Label 1)

Label 1 (Label 1)
This is a prescription label for Lenalidomide Capsules. The label contains information such as the drug's name, dosage instructions, and NDC number. The label also indicates that the drug may cause birth defects and must be dispensed with an accompanying document.*
FDA Label Image

Label 2 (Label 2)

FDA Label Image

Label 3 (Label 3)

FDA Label Image

Label 4 (Label 4)

FDA Label Image

Spl-lenalidomdie-structure (Spl Lenalidomdie Structure)

FDA Label Image

Spl-lenalidomide-image 08 (Spl Lenalidomide Image 08)

Spl-lenalidomide-image 08 (Spl Lenalidomide Image 08)
This appears to be a chart or graph displaying the proportion of subjects along with Kaplan-Meler estimates of time to progression for a study involving lenalidomide/Dex versus placebo/Dex. The HR (hazard ratio) for the two treatments is also given.*
FDA Label Image

Spl-lenalidomide-image 09 (Spl Lenalidomide Image 09)

FDA Label Image

Spl-lenalidomide-image 4 (Spl Lenalidomide Image 4)

FDA Label Image

Spl-lenalidomide-image 5 (Spl Lenalidomide Image 5)

Spl-lenalidomide-image 5 (Spl Lenalidomide Image 5)
This appears to be a graph or chart showing the proportion of subjects in a study and a Kaplan-Meier estimate of time to progression, specifically for Stage 1. It also indicates a Hazard Ratio and Log Rank test result. The x-axis shows time to progression in months and the y-axis displays the proportion of subjects.*
FDA Label Image

Spl-lenalidomide-image-01 (Spl Lenalidomide Image 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.